Other compounds, such as Aescin and Sinomenine (SIN), modulate GBP5 to mitigate symptoms in chemotherapy-induced phlebitis and rheumatoid arthritis, respectively (139, 148). This evidence concerns the gene GBP5 and phlebitis.